Ireland: GH Research prices US$160m IPO on Nasdaq

Psychedelic Brain in Vivid Colors

GH Research, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, priced its Nasdaq IPO on June 24, at US$16 per share to raise approximately US$160m. The offer is set to close June 29. Cowen and Stifel are joint bookrunners. Cannacord Genuity and JMP Securities join them as lead managers….

You must be a HMI Subscriber to view this content.

Subscribe Now »